Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis
Advanced Science · 2025-01 · 12 (4)
DOI: 10.1002/advs.202413408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 05.12.2024. Verfasst von Hanxiao Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, 310000, China. Hauptthemen laut MEDLINE: Exosomes, Copper, Wound Healing. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Zhejiang University School of Medicine Affiliated Second Hospital start-up funds.
Abstract (Originalsprache)
Cuproptosis, caused by an intracellular overload of copper (Cu) ions and overexpression of ferredoxin 1 (FDX1), is identified for its regulatory role in the skin wound healing process. This study verifies the presence of cuproptosis in skin wound beds and reactive oxygen species‐induced cells model. To address the two pathways leading to cell cuproptosis, a nanodrug‐engineered exosomes is proposed. A Cu‐chelator (Clioquinol, CQ) polydopamine (PDA)‐modified stem cell exosome loaded with siRNA‐FDX1, named EXO siFDX1‐PDA@CQ , is designed to efficiently inhibit the two cuproptosis pathways. The functionalized exosomes are loaded into an injectable hydrogel and applied to treat diabetic wounds in mice and acute skin wounds in pigs. The local and controlled release of EXO siFDX1‐PDA@CQ ensures the retention of the therapeutic agent at wound beds, effectively promoting wound healing. The strategy of engineered exosomes with functional nanoparticles (NPs) proposed in this study offers an efficient and scalable new approach for regulating cuproptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, 310000, China.
- College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
ORCID-Profile: Zhengwei Mao, Wei Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Zhejiang University School of Medicine Affiliated Second Hospital start-up funds
Zitieren
APA
Sun, H., Zou, Y., Chen, Z., He, Y., Ye, K., Liu, H., Qiu, L., Zhang, Y., Mai, Y., Chen, X., Mao, Z., Wang, W., & Yi, C. (2025). Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis. Advanced Science, 12(4). https://doi.org/10.1002/advs.202413408
Vancouver
Sun H, Zou Y, Chen Z, He Y, Ye K, Liu H, et al. Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis. Advanced Science. 2025;12(4). doi:10.1002/advs.202413408
BibTeX
@article{Sun2025,
author = {Sun, Hanxiao and Zou, Yang and Chen, Zhengtai and He, Yan and Ye, Kai and Liu, Huan and Qiu, Lihong and Zhang, Yufan and Mai, Yuexue and Chen, Xinghong and Mao, Zhengwei and Wang, Wei and Yi, Chenggang},
title = {Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {4},
doi = {10.1002/advs.202413408}
}
EUVIMED